Cellebrite (CLBT) investor relations material

Executive summary

• Achieved Q1 2026 ARR of $493M, up 21% year-over-year, with revenue of $128.3M, driven by strong subscription growth, AI-driven product launches (Genesis, Guardian Investigate), and rapid adoption across regions and sectors.

• Expanded portfolio with advanced unlock, drone forensics, and FedRAMP High Authorization, positioning for growth in federal and global markets.

• Customer base expanded to ~7,000 globally, with notable penetration in public and private sectors and significant expansions in U.S. federal law enforcement and EMEA defense.

• Leadership transition with Shiv Ramji appointed President of Products and Technology.

• Closed acquisitions of Corellium and SCG Canada, enhancing platform capabilities, especially in drone forensics.

Financial highlights

• Q1 2026 revenue grew 19% year-over-year to $128.3M; subscription revenue up 23% to $117.9M, now 86% of total revenue.

• Adjusted EBITDA was $30.6M (23.9% margin); non-GAAP net income was $30.6M; free cash flow margin at 32% for trailing 12 months.

• Gross profit increased 21% to $110.2M, gross margin at 85–86%.

• Gross revenue retention remained strong at ~92%.

• Weighted average shares outstanding increased to 246.4M in FY26 Q1.

Outlook and guidance

• Q2 2026 ARR expected at $510M–$513M, with revenue of $130M–$133M; full-year 2026 ARR guidance of $567M–$573M and revenue of $565M–$571M, with adjusted EBITDA margin projected at 26–27%.

• Full-year 2026 outlook unchanged, with increased confidence due to expanded portfolio and pipeline.